Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

Successful oral and poster presentations at World Congress of Melanoma and EADO Congress in Athens

At the 11th World Congress of Melanoma and 21st EADO Congress 2025 in Athens, three EUMelaReg studies were sucessfully presented.

The two scientific poster presentations, “Single agent anti-PD-1 versus combined BRAF and MEK inhibitors upfront in metastatic or unresectable BRAF V600 mutated melanoma – A EUMelaReg real-world evidence study” and ”EURO-NMSC: Modern Treatment Usage and Outcome of Patients with Advanced Non-Melanoma Skin Cancer (NMSC) – A Registry Based Cohort Study” attracted a broad and interested audience.

The EUMelaReg real world outcome study "Acral lentiginous melanoma shows a poorer response to immune checkpoint inhibition in the non-resectable or metastatic setting" were presented to a knowledgeable group of experts. It garnered a great deal of attention and gave rise to numerous informative discussions. The oral presentation provided a valuable opportunity to pass on current research findings and exchange ideas with other specialists in the field.